6:03AM Mannkind and Tolero sign collaboration and license agreement to develop and commercialize noval BTK inhibitors for hematological malignancies and inflammatory diseases; MNKD to receive upfront and milestone payments (MNKD) 2.23 : Tolero Pharmaceuticals and MNKD announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases. Under the terms of the agreement, Tolero will pay MannKind upfront and milestone payments linked to the development, approval and commercialization of products, for total potential upfront and milestone payments of ~$130 million. MannKind will also receive tiered royalties on sales of products and a percentage of sublicensing revenue. In addition, MannKind has an option to re-acquire the rights to the program at pre-specified terms until 60 days after the conclusion of the first Phase 1 study. If MannKind exercises this option, then MannKind would assume responsibility for developing and commercializing products and Tolero would become entitled to receive the milestone payments, royalties and sublicensing revenues specified in the agreement.